WO2004093858A1 - Mmp発現抑制剤 - Google Patents
Mmp発現抑制剤 Download PDFInfo
- Publication number
- WO2004093858A1 WO2004093858A1 PCT/JP2004/006038 JP2004006038W WO2004093858A1 WO 2004093858 A1 WO2004093858 A1 WO 2004093858A1 JP 2004006038 W JP2004006038 W JP 2004006038W WO 2004093858 A1 WO2004093858 A1 WO 2004093858A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmp
- menatetrenone
- expression
- cancer
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a medicament characterized by inhibiting the expression of extracellular matrix metalloproteinase (MMP) by cancer cells.
- MMP matrix metalloproteinase
- the extracellular matrix (sometimes called ECM: extracellular matrix) is a generic term for insoluble components that fix and adhere to the cells that make up a multicellular organism.
- the extracellular matrix is known to affect its proliferation and differentiation through adhesion to cells, the main ones being collagen, fibronectin, laminin and the like.
- Extracellular matrix is an extracellular matrix degrading enzyme
- MMP matrix metalloproteinase, hereafter referred to as IMMP.
- MMP matrix metalloproteinase, hereafter referred to as IMMP.
- IMMP matrix metalloproteinase
- the present inventors have surprisingly found that menatetrenone (vitamin ⁇ - ⁇ ) suppresses the expression of MMP.
- An object of the present invention is to suppress the expression of MMP.
- An object of the present invention is to provide a highly safe drug having an effect of suppressing the growth of cancer cells.
- the present invention relates to (1) an MMP expression inhibitor containing menatetrenone or a pharmacologically acceptable salt thereof or a hydrate thereof as an active ingredient, (2) the MMP, wherein MMP_1,
- a uPA expression inhibitor which contains hydrate as an active ingredient; (4) suppresses metastasis and invasion of cancer, which contains menatetrenone or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient (5) the cancer metastasis or invasion inhibitor according to claim 4, wherein the cancer is liver cancer, (6) menatetrenone, a pharmacologically acceptable salt thereof or a hydrate thereof is effective.
- Activity inhibitor of AP-1 contained as an ingredient, (7) menatetrenone or An Ets-1 expression inhibitor containing the pharmacologically acceptable salt or hydrate thereof as an active ingredient, (8) menatetrenone or a pharmaceutically acceptable salt thereof or a hydrate thereof.
- a method for inhibiting metastasis of cancer cells, (10) a CDK inhibitor pl6, p21 or p27, which comprises menatetrenone or a pharmacologically acceptable salt thereof or a hydrate thereof as an active ingredient, provide.
- FIG. 1 (a) is a graph showing the relationship between the amount of menatetrenone added and the proliferation of various liver cancer cells.
- B shows the results of experiments by T-PCR showing the relationship between the amount of menatetrenone added and the expression of CDK inhibitor in various liver cancer cells.
- C shows the results of Western blot analysis showing the relationship between the amount of menatetrenone added and the expression of CDK inhibitors in various liver cancer cells.
- Figure 2 shows the cell cycle when menatetrenone was added to various types of liver cancer cells. is there.
- FIG. 3 is a view showing the results of suppressing the invasion of hepatoma cells when menatetrenone was added to hepatoma cells.
- FIG. 4 is a diagram showing the results of experiments using RT-PCR for the expression of various invasion-related factors when menatetrenone was added to various liver cancer cells.
- FIG. 5 is a graph showing the results of Western blot analysis of the expression of various invasion-related factors when menatetrenone was added to various liver cancer cells.
- FIG. 6 is a diagram showing the results of an experiment using gel shift assay for activation of transcription factors when adding menatetrenone.
- FIG. 7 is a diagram showing the results of an RT-PCR experiment on the effect of various MMPs on the promoter activity when menatetrenone is added to hepatoma cells.
- FIG. 8 is a diagram showing the results of RT-PCR experiments on the effect of menatetrenone on the expression of genes related to invasion and metastasis of cancer induced by TPA.
- FIG. 9 shows the results of Western blot analysis of the effect of menatetrenone on the expression of proteins associated with invasion and metastasis of cancer induced by TPA.
- Menatetrenone is a yellow crystalline or oily substance that has no smell and taste and is easily decomposed by light. It is hardly soluble in water. Menatetrenone is also called vitamin K-II, and its pharmacological action is to convert glutamic acid residues into ⁇ -carboxigglutamic acid, which has physiological activity, during the process of protein synthesis of blood coagulation factors (prothrombin, VII, IX, X) It promotes the synthesis of normal prothrombin and the like in the liver, activates the hemostatic mechanism of the living body, and exerts a physiological hemostatic action.
- blood coagulation factors prothrombin, VII, IX, X
- the “pharmacologically acceptable salt” in this effort includes, for example, a salt with an inorganic acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, and a salt with an acidic or basic amino acid. And the like. Acids and bases form salts at an appropriate ratio of 0.1 to 5 molecules to 1 molecule of the compound.
- salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Preferred examples of salts with organic acids include, for example, acetic acid And salts with succinic acid, fumaric acid, maleic acid, tartaric acid, cunic acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, and ⁇ -toluenesulfonic acid.
- Preferred examples of the salt with an inorganic base include an alkali metal salt such as a sodium salt and a potassium salt, an alkaline earth metal salt such as a calcium salt and a magnesium salt, an aluminum salt, an ammonium salt and the like.
- Preferred examples of the salt with an organic base include getylamine, diethanolamine, and meg. Examples include salts with noremin, ⁇ , ⁇ ′-dibenzylethylenediamine and the like.
- Preferred examples of the salt with an acidic amino acid include, for example, salts with aspartic acid and glutamic acid.
- Preferred examples of the salt with the basic amino acid include, for example, arginine, lysine, orditin and the like. And salts thereof.
- Menatetrenone which is an active ingredient of the medicament according to the present invention, may be an anhydride or may form a hydrate. Menatetrenone may have a crystalline polymorph, but is not limited thereto. The crystalline form may be a single crystalline form or a mixture of plural crystalline forms. Further, metabolites generated by decomposing menatetrenone according to the present invention in a living body are also included in the scope of the claims of the present invention.
- Menatetrenone used in the present invention can be produced by a method known per se. As a typical example, menatetrenone is easily produced according to the method disclosed in JP-A-49-56550. In addition, they can be easily obtained from synthetic manufacturers. Menatetrenone is also available as capsenole and injection preparations.
- menatetrenone may be used as it is, or a pharmaceutically acceptable carrier known per se (eg, excipients, binders, disintegrants, lubricants, coloring agents, Flavoring agents, stabilizers, emulsifiers, absorption enhancers, surfactants, ⁇ adjusters, preservatives, antioxidants, etc.) and ingredients commonly used as raw materials for pharmaceutical preparations May be formulated. Further, if necessary, components such as vitamins, amino acids and the like may be added. Examples of the dosage form for preparation include tablets, powders, fine granules, granules, capsules, syrups, suppositories, injections, ointments, cataplasms and the like.
- menatetrenone capsenole is available under the brand name Kate I Capsule (Eisai Co., Ltd.) and Graquet I Capsule (Eisai Co., Ltd.).
- the syrup is available under the brand name K2 Syrup (Eisai Co., Ltd.). Is available under the trade name K2 ⁇ Note (made by Eisai Co., Ltd.) it can.
- menatetrenone is 1-50 Omg / 'day, preferably 10-200 mg / day, more preferably 30-135 mg / day.
- MMP refers to matrix metalloproteinase as described above.
- uPA urokinase plasminogen activator
- PA puffinogen activator
- the inventors conducted the following test to study how menatetrenone affects (1) proliferation and (2) invasion / metastasis of cancer cells.
- GAPDH Glyceraldehyde 3-phosphate dehydrogenase
- p27 and p21 mRNAs were increased in HepG2 cells depending on the concentration of added menatetrenone.
- p21 and pl6 were slightly increased. No change in p27 was observed, and there was no change in their expression in Huh7 cells.
- menatetrenone increased the ratio of G1-phase cells in all cells in a concentration-dependent manner, This suggests that menatetrenone suppresses the progression from G1 to S phase in the cell cycle of liver cancer cells, and that menatetrenone induces G1 arrest. It is thought that the proliferation of hepatoma cells was suppressed.
- menatetrenone in hepatoma cells 0 ⁇ , 1 ( ⁇ 6 ⁇ , 1 ( ⁇ 5 ⁇ , at a concentration of 1 (gamma 4 Micromax
- the infiltration ability of the cancer cells into Matrigel was measured
- Matrigel was coated on the upper chamber of the double jumper, the cancer cells were spread thereon, and menatetrenone was added.
- ⁇ 3 ⁇ 3 cells were seeded, and 24 hours later, the number of cells that had passed through Matrigel and migrated to the lower surface of the upper chamber was observed under a microscope The results are shown in Figure 3.
- ⁇ -1, ⁇ _3, MMP-7 and MMP-14 mRNA levels increased with the addition of menatetrenone. It can be seen that it is suppressed in a dependent manner.
- the expression of the transcription factor Ets-1 was suppressed in a concentration-dependent manner, and there was no change in the mRNA expression of ⁇ ⁇ integrin and GAPDH.
- MMP-1 and MMP-3 were investigated when menatetrenone was added to various liver cancer cells (HepG2, Hep3B, Huh7).
- Fig. 5 shows the results. As is clear from FIG. 5, the expression of MMP-1 and MMP-3 proteins was suppressed by the addition of menatetrenone.
- MMPs have binding sites for transcription factors AP-1, Ets-1, Tcf / Lef, etc. in common with their promoter regions, and are known to regulate MMP expression. .
- a test was performed by gel shift assay to determine whether the binding activity of the transcription factors AP-1 and Tcf / Lef, which regulates the expression of MMP, was altered by the addition of menatetrenone. In this test, menatetrenone was added to liver cancer cells HepG2 and nuclear proteins were extracted 24 hours later. 0
- FIG. 6 shows the results.
- menatetrenone did not change the binding activity of Tcf / Lef, but suppressed the binding activity of AP-1 in a concentration-dependent manner.
- This binding was attenuated in a concentration-dependent manner with an excess of unlabeled AP-1 probe ("10X", "100X” in the figure), and was unchanged with the mutant AP-1 probe (Fig. “MJ” in the figure, and band attenuation and shift were observed with the anti-c-fos antibody (“S” in the figure). From the above results, it was found that menatetrenone specifically inhibited AP-1 binding. (MMP gene promoter activity test)
- MMP-1, MMP_3, and MMP-7 promoter reporter genes were introduced into hepatoma cells Huh7, and the effect of menatetrenone on these MMP promoter activities was examined.
- MMP-1, MMP-3, and MMP-7 promoter-luciferase porter plasmids are the reporters of the MMP promoter motor-CAT reporter plasmid (Reference 1) reported in Reference 1 below. The one created by replacing the gene part was used.
- Fig. 7 shows the results.
- the addition of menatetrenone caused the promoter activity of MMP-1, MMP-3, and MMP-7 in Huh7 cells to increase. It was suppressed in a concentration-dependent manner. In particular, the activity of MMP-1 and MMP-7 was reduced by nearly 50%. This indicates that the suppression of MMP expression by menatetrenone is caused by the suppression of these gene promoter motor activities. (Test of gene expression during induction by TPA)
- TPA 12-0-tetradecanoylphorbol-13-acetate
- menatetrenone inhibits the expression of the transcription factor Ets-1 and the binding activity of AP-1, and is characterized by MMP and MMP, which are enzymes that degrade extracellular matrix. Both suppress and prevent the expression of uPA, an enzyme involved in cancer invasion and metastasis, thereby suppressing invasion and metastasis of cancer cells.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005505815A JPWO2004093858A1 (ja) | 2003-04-23 | 2004-04-23 | Mmp発現抑制剤 |
US10/553,434 US20060194883A1 (en) | 2003-04-23 | 2004-04-23 | Mmp expression inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-118581 | 2003-04-23 | ||
JP2003118581 | 2003-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004093858A1 true WO2004093858A1 (ja) | 2004-11-04 |
Family
ID=33308076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006038 WO2004093858A1 (ja) | 2003-04-23 | 2004-04-23 | Mmp発現抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060194883A1 (ja) |
JP (1) | JPWO2004093858A1 (ja) |
CN (1) | CN1777413A (ja) |
WO (1) | WO2004093858A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007091557A1 (ja) * | 2006-02-10 | 2007-08-16 | National University Corporation Nagoya University | 肝癌治療又は予防用医薬組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
US9334500B2 (en) | 2011-09-28 | 2016-05-10 | Agency For Science, Technology And Research | Methods and pharmaceutical compositions for treating cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06305955A (ja) * | 1993-04-27 | 1994-11-01 | Eisai Co Ltd | キノン系細胞分化誘導剤 |
JP2004067513A (ja) * | 2002-06-12 | 2004-03-04 | Eisai Co Ltd | キノン系肝疾患治療剤 |
JP2004107330A (ja) * | 2002-08-26 | 2004-04-08 | Eisai Co Ltd | キノン系肝疾患治療剤 |
WO2004056351A1 (ja) * | 2002-12-20 | 2004-07-08 | Eisai Co., Ltd. | Pka活性調節剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0681739B2 (ja) * | 1988-07-11 | 1994-10-19 | エーザイ株式会社 | 脂溶性ビタミンk含有水性液 |
US7138433B2 (en) * | 2002-09-16 | 2006-11-21 | Eisai Co., Ltd. | Quinone-based therapeutic agent for hepatopathy |
-
2004
- 2004-04-23 CN CNA2004800105099A patent/CN1777413A/zh active Pending
- 2004-04-23 WO PCT/JP2004/006038 patent/WO2004093858A1/ja active Application Filing
- 2004-04-23 JP JP2005505815A patent/JPWO2004093858A1/ja not_active Withdrawn
- 2004-04-23 US US10/553,434 patent/US20060194883A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06305955A (ja) * | 1993-04-27 | 1994-11-01 | Eisai Co Ltd | キノン系細胞分化誘導剤 |
JP2004067513A (ja) * | 2002-06-12 | 2004-03-04 | Eisai Co Ltd | キノン系肝疾患治療剤 |
JP2004107330A (ja) * | 2002-08-26 | 2004-04-08 | Eisai Co Ltd | キノン系肝疾患治療剤 |
WO2004056351A1 (ja) * | 2002-12-20 | 2004-07-08 | Eisai Co., Ltd. | Pka活性調節剤 |
Non-Patent Citations (9)
Title |
---|
KOIKE Y. ET AL.: "Monmyakunai shuyo shinjun (PVI) yobo o mokuteki to shita vitamin KII toyo ni yoru randomized prospective controlled study", ACTA HEPATOLOGICA JAPONICA, vol. 43, no. SUPPL. 1, 2002, pages A64, XP002984759 * |
MIYAGAWA T. ET AL.: "Vitamin K no kogan sayo", VITAMIN, vol. 74, no. 2, 2000, pages 74 - 76, XP002984763 * |
MIYAZAWA K. ET AL.: "Combined treatment of leukemia cells with lalpha, 25-dihydroxy-22-oxavitamin D3 plus vitamin K2 (VK2), results in synergistic enhancement of monocytic differentiation but also inhibition of VK2-inducing apoptosis by cytoplasmic p21CIP1", BLOOD, MEETING INFO: 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 98, no. 11, 2001, pages 353A, XP002984760 * |
MIZUTA T. ET AL.: "Vitamin K ni yoru kansaibo gan saihatsu yokusei koka no rinshoteki kento", JAPANESE JOURNAL OF GASTROENTEROLOGY, vol. 99, 2002, pages A192, XP002984758 * |
MIZUTA T. ET AL.: "VItamin K toyo ni yoru kansaibo gan saihatsu yokusei koka no kento", DAI 38 KAI NIHON KANGAN KENKYUKAI SYOROKUSHU, 2002, pages 135, XP002984757 * |
NISHIKAWA Y. ET AL.: "Growth inhibition of hepatoma cells induced by vitamin K and its analogs", J. BIOL. CHEM., vol. 270, no. 47, 1995, pages 28304 - 28310, XP002984762 * |
OKAYASU H. ET AL.: "Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines", ANTICANCER RESEARCH, vol. 21, 2001, pages 2387 - 2392, XP002984761 * |
OTSUKA M. ET AL.: "Inhibition of hepatoma cell growth and invasion by vitamin K2 administration in vitro", HEPATOLOGY, MEETING INFO: 53RD ANNUAL MEETING ON THE LIVER, vol. 36, no. 4, 2002, pages 445A, XP002984756 * |
WU F.Y.-H. ET AL.: "Comparison of antitumor activity of vitamins K1. K2, and K3 on human tumor cells by two (mit and srb), cell viability assays", LIFE SCIENCE, vol. 52, no. 22, 1993, pages 1797 - 1804, XP002286387 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007091557A1 (ja) * | 2006-02-10 | 2007-08-16 | National University Corporation Nagoya University | 肝癌治療又は予防用医薬組成物 |
JP2007210967A (ja) * | 2006-02-10 | 2007-08-23 | Univ Nagoya | 肝癌治療又は予防用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20060194883A1 (en) | 2006-08-31 |
JPWO2004093858A1 (ja) | 2006-07-13 |
CN1777413A (zh) | 2006-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-κB pathway | |
Ota et al. | Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism | |
Jamart et al. | Prevention of muscle disuse atrophy by MG132 proteasome inhibitor | |
CA2933590C (en) | Glucocorticoid inhibitors for treatment of prostate cancer | |
JP2021050218A (ja) | チロシンキナーゼ阻害剤を用いる組成物および方法 | |
CN106456635A (zh) | Mdm2抑制剂的间歇给药 | |
JP2005527510A (ja) | 癌の治療において一酸化窒素模倣体を使用するための製剤および方法 | |
Hua et al. | P7C3‐A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP‐activated protein kinase/CREB regulated transcription coactivator 2 pathway | |
JP2019026649A (ja) | 結腸直腸癌を処置する方法 | |
Eisenhardt et al. | ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction | |
US8785423B2 (en) | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases | |
EP3878470A1 (en) | Method for removing senescent cell, and method for preparing senescent cell | |
Chia et al. | Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice | |
CN101489580A (zh) | 治疗或预防hcv感染症的药物组合物 | |
WO2004093858A1 (ja) | Mmp発現抑制剤 | |
EP3463387A1 (en) | Medicament for the treatment of acute liver failure | |
EP3810810B1 (en) | Cancer treatment methods based on tp53 mutation status and hypermutation status | |
Foulquier et al. | Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR | |
Foldes et al. | The influence of glucocorticoids on plasma cholinesterase | |
JP2013521284A (ja) | ウィルス性疾患の治療のための組成物及び方法 | |
JP5891315B2 (ja) | Tenc1の発現または活性抑制剤を含む糖尿病の予防または治療用の薬学的組成物 | |
WO2015009879A1 (en) | Compositions for modulating nrf2-are activity and their methods of use | |
ES2378896T3 (es) | Combinación de fármacos que contiene Probucol y un derivado de tetrazolilalcoxi-dihidrocarbostirilo con efectos inhibidores del superóxido | |
CN116271033A (zh) | 一种以sqle基因或蛋白为靶点治疗克唑替尼肝脏毒性的药物 | |
Song et al. | Up-regulation of TGF-β via the activation of extracellular signal-regulated kinase 1 and 2 induced by prorenin in human renal mesangial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505815 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006194883 Country of ref document: US Ref document number: 10553434 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048105099 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10553434 Country of ref document: US |